| Clinical Trial Name | Clinical Trial Full Title | Principal Investigator | Project site status | Clinical trials gov number |
|---|---|---|---|---|
| (Astellas) 7465-CL-0301 | An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) | Hotte, Dr Sebastien | Open to recruitment | NCT03474107 |
| (AstraZeneca) D419JC00001 / POTOMAC | A Phase III Randomized, Open-Label, Multi-Center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Therapy Versus BCG Alone in High-Risk, BCG-Naïve Non-Muscle-Invasive Bladder Cancer Patients (POTOMAC) | Hotte, Dr Sebastien | Open to recruitment | NCT03528694 |
| (AstraZeneca) D933SC00001 / NILE | A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer | Hotte, Dr Sebastien | Open to recruitment | NCT03682068 |
| (BMS) CA018005 / FRACTION-RCC | A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma | Hotte, Dr Sebastien | Open to recruitment | NCT02996110 |
| (BMS) CA2099KD / CheckMate 9KD | A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer (CheckMate 9KD: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9KD) | Hotte, Dr Sebastien | Open to recruitment | NCT03338790 |
| (CCTG) IND.234 / PC-BETS - Master Protocol | Prostate Cancer Biomarker Enrichment and Treatment Selection (PC_BETS) Study - Master Screening Protocol | Mukherjee, Dr Som | Open to recruitment | NCT03385655 (Master) |
| (CCTG) IND.234 / PC-BETS - Sub-Study IND.223 | A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients With Metastatic Castration-Resistant Prostate Cancer | Mukherjee, Dr Som | Open to recruitment | NCT02905318 |
| (CCTG) IND.234B/PC-BETS Sub-Study B | A Phase II Study of Savolitinib, A CMET Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234 | Mukherjee, Dr Som | Open to recruitment | NCT03385655(B) |
| (CCTG) IND.234C/PC-BETS Sub-Study C | A Phase II Study of Darolutamide (ODM-201) in Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate or Enzalutamide - A Sub-Study of IND.234 | Mukherjee, Dr Som | Open to recruitment | NCT03385655(C) |
| (Clovis) CO-338-052 / TRITON2 | A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency | Hotte, Dr Sebastien | Open to recruitment | NCT02952534 |
| (JCC) Prostate HBI | Non-Targeted Low Dose Radiotherapy For Recurrent Prostate Cancer | Dayes, Dr Ian | Open to recruitment | NCT03196778 |
| (JGH) PCS IX / PCS 9 | The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer With Oligometastases: An Adaptive Phase II/III Randomized Trial. | Tsakiridis, Dr Theos | Open to recruitment | NCT02685397 |
| (Merck) MK-3475-564 / KEYNOTE 564 | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) | Lalani, Dr Aly-Khan | Open to recruitment | NCT03142334 |
| (Merck) MK-3475-641 / KEYNOTE 641 | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Lalani, Dr Aly-Khan | Open to recruitment | NCT03834493 |
| (Merck) MK-3475-921 / KEYNOTE 921 | A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA) | Lalani, Dr Aly-Khan | Open to recruitment | NCT03834506 |
| (Merck) MK-7339-010 / KEYLYNK-010 | Phase 3, Randomized, Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy | Lalani, Dr Aly-Khan | Open to recruitment | NCT03834519 |
| (Bayer) BAY 1163877 / 17403 / FORT-1 | A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum containing chemotherapy | Hotte, Dr Sebastien | Suspended/On hold | NCT03410693 |
| (CCTG) IND.234A/PC-BETS Sub-Study A | A Phase II Study of AZD1775, A WEE1 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234 | Mukherjee, Dr Som | Suspended/On hold | NCT03385655 (A) |
| (JCC) The PBS Study | A randomized phase II trial investigating Stereotactic Body RadioTherapy (SBRT) for prostate boost irradiation in the treatment of high risk Prostate Cancer (PrCa) | Tsakiridis, Dr Theos | Suspended/On hold | NCT03380806 |
| OCOG-2013-PETMUSE | Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging | Mukherjee, Dr Som | Suspended/On hold | NCT02462239 |
Find a Trial
Contact Us